-
The Journal of Family Practice May 1994
Topics: Adult; Female; Humans; Male; Mathematics; Vancomycin
PubMed: 8195725
DOI: No ID Found -
The Journal of Antimicrobial... Aug 1988
Topics: Humans; Vancomycin
PubMed: 3182422
DOI: 10.1093/jac/22.2.265 -
Medecine Et Maladies Infectieuses May 2020Staphylococcusaureus is involved in around 20% of nosocomial pneumonia cases. Vancomycin used to be the reference antibiotic in this indication, but new molecules have... (Comparative Study)
Comparative Study Observational Study
OBJECTIVE
Staphylococcusaureus is involved in around 20% of nosocomial pneumonia cases. Vancomycin used to be the reference antibiotic in this indication, but new molecules have been commercialized, such as linezolid. Previous studies comparing vancomycin and linezolid were based on models. Comparing their real costs from a hospital perspective was needed.
METHODS
We performed a bicentric retrospective analysis with a cost-minimization analysis. The hospital antibiotic acquisition costs were used, as well as the laboratory test and administration costs from the health insurance cost scale. The cost of each hospital stay was evaluated using the national cost scale per diagnosis related group (DRG), and was then weighted by the stay duration.
RESULTS
Fifty-eight patients were included. All bacteria identified in pulmonary samples were S. aureus. The cost of nursing care per stay with linezolid was €234.10 (SD=91.50) vs. €381.70 (SD=184.70) with vancomycin (P=0.0029). The cost of laboratory tests for linezolid was €172.30 (SD=128.90) per stay vs. €330.70 (SD=198.40) for vancomycin (P=0.0005). The acquisition cost of linezolid per stay was not different from vancomycin based on the price of the generic drug (€54.92 [SD=20.54] vs. €40.30 [SD=22.70]). After weighting by the duration of stay observed, the mean cost per hospital stay was €47,411.50 for linezolid and €57,694.0 for vancomycin (NSD).
CONCLUSION
These results, in favor of linezolid, support other former pharmacoeconomic study based on models. The mean cost per hospitalization stay was not statistically different between the two study groups, but a trend in favor of linezolid is emerging.
Topics: Aged; Costs and Cost Analysis; Cross Infection; Diagnosis-Related Groups; Drug Costs; Economics, Nursing; Female; France; Hospitalization; Hospitals, Urban; Humans; Infusions, Intravenous; Length of Stay; Linezolid; Male; Middle Aged; Pneumonia, Staphylococcal; Retrospective Studies; Staphylococcus aureus; Vancomycin
PubMed: 31387813
DOI: 10.1016/j.medmal.2019.07.012 -
Reviews of Infectious Diseases 1981The emergence of antibiotic-resistant strains of Staphylococcus aureus in hospitalized patients during the early 1950s stimulated research designed to develop new... (Clinical Trial)
Clinical Trial
The emergence of antibiotic-resistant strains of Staphylococcus aureus in hospitalized patients during the early 1950s stimulated research designed to develop new antimicrobial agents that would combat the "golden plague." Vancomycin, produced by a microorganism found in a soil sample from the jungle trails of Borneo, was shown to have antistaphylococcal activity and to be relatively safe when administered to patients with staphylococcal infections. In a recent resurgence in the use of vancomycin, investigators have reported the value of this antibiotic in the treatment of staphlococcal infections against which the newer antistaphylococcal antibiotics are ineffective. In addition, vancomycin is being used for prophylaxis in patients undergoing renal dialysis, for treatment of antibiotic-induced enterocolitis, and in combination with an aminoglycoside for "sterilization" of the intestinal tract of patients with cancer.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Humans; Staphylococcal Infections; Staphylococcus; Vancomycin
PubMed: 7043707
DOI: No ID Found -
The Annals of Pharmacotherapy Dec 1994
Comparative Study
Topics: Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Humans; Kidney Diseases; Liability, Legal; Renal Dialysis; Vancomycin
PubMed: 7696733
DOI: 10.1177/106002809402801212 -
Nederlands Tijdschrift Voor Geneeskunde 2011To compare the efficacy of continuous vancomycin infusion with intermittent vancomycin infusion based on clinical endpoints. (Comparative Study)
Comparative Study Review
OBJECTIVE
To compare the efficacy of continuous vancomycin infusion with intermittent vancomycin infusion based on clinical endpoints.
DESIGN
Systematic review of the literature.
METHOD
Sixty articles on comparative studies on continuous and intermittent vancomycin infusion were found in Pubmed. Of these, the English-language articles on studies in adults were selected. Only articles in which a comparison was made in terms of clinical endpoints were included.
RESULTS
Six studies were included in which the differences between continuous and intermittent infusions were assessed in terms of the clinical endpoints. In the 2 prospective studies, no statistically significant differences in efficacy between the two methods of administration were found. A prospective study and retrospective study suggested that continuous infusion of high-dose vancomycin in patients with osteomyelitis may be more effective than intermittent infusion. There were no clear differences in side effects, although nephrotoxicity seemed to occur less rapidly and less often with continuous vancomycin infusion.
CONCLUSION
The available literature showed that continuous infusion of vancomycin is as effective as intermittent administration. In addition, continuous administration is cheaper and monitoring of serum levels is simpler. This offers the possibility of discharging specific patients more quickly from hospital and facilitates home care with vancomycin.
Topics: Anti-Bacterial Agents; Humans; Infusions, Intravenous; Treatment Outcome; Vancomycin; Vancomycin Resistance
PubMed: 22027450
DOI: No ID Found -
Arthroscopy : the Journal of... May 2022Soaking anterior cruciate ligament grafts in vancomycin solution is done by many surgeons. Research has indicated decreased infection rates and similar anterior cruciate...
Soaking anterior cruciate ligament grafts in vancomycin solution is done by many surgeons. Research has indicated decreased infection rates and similar anterior cruciate ligament retear rates between grafts soaked in vancomycin solution before implantation versus those without. In addition, there has been basic science evidence for tenocyte survival and viability even when exposed to vancomycin solution. The next frontier, investigating the maturation of vancomycin-soaked grafts with advanced imaging, may cause some surgeons to reconsider the practice but should not stop it, based on the available literature.
Topics: Anterior Cruciate Ligament; Anterior Cruciate Ligament Injuries; Anterior Cruciate Ligament Reconstruction; Humans; Vancomycin
PubMed: 35501018
DOI: 10.1016/j.arthro.2021.11.022 -
Nephrologie & Therapeutique Apr 2018Vancomycin, discovered in 1953 and widely used today, has a nephrotoxic potential that has long been debated. The frequency of renal involvement is variable and can...
Vancomycin, discovered in 1953 and widely used today, has a nephrotoxic potential that has long been debated. The frequency of renal involvement is variable and can range from 5% to 30% depending concomitant risk factors: overdose, chronic kidney disease, obesity, hypovolemia, and use of other nephrotoxic drugs as aminoglycosides. Its association with piperacillin-tazobactam also appears to increase the risk of nephrotoxicity. This hypothesis should be confirmed experimentally. Vancomycin-induced oxidative stress in tubular cells and intraluminal cast formation are the two physiopathological mechanisms explaining its nephrotoxicity. Vancomycin may induce acute tubular injury and rapid decline in renal function. These lesions are often reversible when the infusion is discontinued, but sometimes chronic kidney failure may ensue. As vancomycin is widely used and the current tendency is to increase target trough levels, it is necessary to identify risk factors in order to reduce its risk of nephrotoxicity.
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Humans; Kidney; Risk Factors; Vancomycin
PubMed: 29606259
DOI: 10.1016/j.nephro.2018.02.009 -
American Journal of Diseases of... Jan 1984
Topics: Adult; Aminoglycosides; Bacterial Infections; Child; Drug Synergism; Humans; Infant; Infant, Newborn; Infusions, Parenteral; Skin Diseases; Vancomycin
PubMed: 6691309
DOI: 10.1001/archpedi.1984.02140390006003 -
Pharmacotherapy Dec 2013
Topics: Adult; Anti-Bacterial Agents; Child; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Practice Guidelines as Topic; Vancomycin
PubMed: 24302197
DOI: 10.1002/phar.1382